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ABSTRACT
Background. Esophageal squamous cell carcinoma is an
aggressive gastrointestinal tract cancer. To date, the pres-
ence of circulating tumor cells (CTC) has been reported as
a prognostic factor in peripheral blood from patients with
gastrointestinal cancers.
Methods. The CellSearch system was used to isolate and
enumerate CTCs. A total of 90 patients with esophageal
squamous cell carcinoma who received chemotherapy or
chemoradiotherapy were enrolled. Peripheral blood speci-
mens were collected before and after treatments.
Results. At baseline analysis, CTCs were detected in 25
patients (27.8 %). Overall survival was significantly
shorter in patients with than without CTCs. Follow-up
blood specimens were obtained from 71 patients. Partial
response, stable disease, and progressive disease after
treatment were seen in 32, 12, and 27 patients, respectively.
CTC positivity after treatment in the progressive disease
group (40.7 %) was significantly higher than that of the
partial response group (6.3 %). Patients with a change in
CTC status from positive to negative had a good prognosis
as well as patients without baseline CTCs.
Conclusions. Evaluation of CTCs may be a promising
indicator for predicting tumor prognosis and the clinical
efficacy of chemotherapy or chemoradiation therapy in
patients with esophageal squamous cell carcinoma.
Esophageal squamous cell carcinoma (ESCC) is an ag-
gressive gastrointestinal tract cancer.1 Even after curative
surgical resection, some patients develop recurrent disease.
To date, the presence of circulating tumor cells (CTCs) in
blood specimens obtained from patients with gastroin-
testinal tract cancers, including ESCC, has been
reported.2–5 Early detection of CTCs may be important
information prior to various treatments, including surgery,
chemotherapy, and chemoradiation therapy (CRT). For
instance, if CTCs in peripheral blood are confirmed before
surgery, the induction of neoadjuvant therapy may be
indicated. Accordingly, the presence or absence of CTCs
may impact the timing of surgical intervention. Further-
more, the presence of CTCs would be a useful indicator to
evaluate the clinical effects of chemotherapy and CRT.
Until now, the detection of rare CTCs has been attempted
by a molecular biological approach, such as reverse-tran-
scription polymerase chain reaction (RT-PCR) and flow
cytometry, in gastrointestinal tract cancers,5–11 although
the clinical significance of CTCs in ESCC remains unclear.
In particular, RT-PCR has been reported to be a useful tool
to detect CTCs and predict tumor progression in ESCC
patients.12 However, high sensitivity and reproducibility
would be required for the detection of CTCs from blood
specimens with the molecular approach. The CellSearch
System (Janssen Diagnostics, LLC, Raritan, NJ) has been
developed to identify CTCs in blood, and it has clinical
utility to predict tumor progression and prognosis in pa-
tients with metastatic breast and prostate cancers.13,14
There are a few reports regarding CTCs using the
CellSearch System in ESCC patients.15 Our hypothesis was
that CTCs in ESCC patients are associated with
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progression and prognosis. In this study, CTCs were
evaluated using the CellSearch system in ESCC patients,
and their clinical impact was assessed.
MATERIALS AND METHODS
ESCC Cell Line
To evaluate the sensitivity of the CellSearch system
in vitro, five esophageal squamous cell carcinoma cell li-
nes, TE8, TE9 (Riken BioResource Center), KYSE50,
KYSE220, and KYSE270, were used.16 KYSE50 was
cultured in DMEN (Miltenyi Biotec K.K., Tokyo, Japan).
KYSE220, KYSE270, TE8, and TE9 were cultured in a
medium with a 1 to 1 mixture of RPMI 1640 (Nissui
Pharmaceutical Co., Ltd., Tokyo, Japan) and F-12 HAM
(Sigma-Aldrich Co. LLC., USA). Each culture medium
was supplemented with 10 % fetal calf serum (Mitsubishi
Kasei, Tokyo, Japan), 100 units/mL of penicillin, and 100
units/mL of streptomycin. Cancer cells were grown at
37 C in a humidified atmosphere containing 5 % CO2, as
previously described.16,17
Clinical Study Design
ESCC patients who were treated at Kagoshima
University Hospital were analyzed using prospectively
collected data. Informed consent was obtained from all
patients in accordance with the ethical standards of the
Committee on Human Experimentation of Kagoshima
University Hospital, Japan.
A total of 103 consecutive patients with advanced ESCC
were enrolled from July 2011 to January 2014. Thirteen
patients with another advanced cancer, such as gastric,
colorectal, or prostate cancer, were excluded from this study.
A total of 90 patients without previous treatment were en-
rolled for the analysis. Fifty-seven patients (63.3 %) were
still alive at the time of the analysis. Patients were classified
and staged on the basis of the criteria in the seventh edition of
the tumor-node-metastasis (TNM) classification of esopha-
geal cancer established by the Union for International Cancer
Control (UICC).18 The clinicopathological features are
shown in Table 1. Distant metastases were observed in 28
patients. Twenty patients had hematogenous metastases.
Pleural dissemination was found in six patients, and distant
lymph node metastases involving, for example, the para-
aortic, axial, and inguinal lymph nodes, were identified in ten
patients. The number of patients in each clinical stage was 2
cases in II, 12 cases in IIIa, 12 cases in IIIb, 36 cases in IIIc,
and 28 cases in IV, respectively.
All patients were tested with serum tumor markers,
such as carcinoembryonic antigen (CEA), squamous cell
carcinoma antigen (SCC), and C-reactive protein (CRP),
as an inflammatory marker. Sixty-four patients received
CRT, and 26 patients were treated with chemotherapy
alone. Chemotherapy was provided by a high-dose FP
regimen using 5-fluorouracil and cisplatin or by a DCS
regimen using docetaxel, cisplatin, and S-1. CRT con-
sisted of intravenous chemotherapy using an FP regimen
and a total radiation dose of 40–60 Gy in the same pe-
riod.19,20 In this study, 36 cases were treated as a
neoadjuvant therapy, and another 54 patients were treated
as an unresectable case. A total of 16 patients underwent
surgical resection after treatment. Fourteen patients re-
ceived surgical resection after neoadjuvant therapy, and
two cases who were diagnosed with progressive disease
after chemotherapy received surgical resection as a sal-
vage surgery.
TABLE 1 Characteristics of patients with ESCC (n = 90)
Total (n = 90)
Gender Male/female 78/12
Age Average (range) 65.0 years (46–98)
cT factor 1/2/3/4a/4b 4/4/49/4/29
cN factor 0/1/2/3 1/12/28/49
cM factor 0/1 62/28
cStage IIa/IIIa/IIIb/IIIc/IV 2/12/12/36/28
Serum CEA Negative/positive 75/15
Serum SCC Negative/positive 33/57
CRP \0.4/C0.4 39/51
Treatment Chemotherapy/CRT 26/64
Surgical resection after treatment No/yes 74/16
cT cN cM factors were diagnosed using UICC 7th edition
cT factor depth of primary tumor, cN factor lymph node metastatic status, cM factor status of distant metastasis, including distant lymph node
metastasis, CEA carcinoembryonic antigen, SCC squamous cell carcinoma antigen, CRP C-reaction protein, CRT chemoradiation therapy
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Peripheral blood was collected for the baseline analysis
before starting treatments, and peripheral blood specimens
were obtained from 15 healthy volunteers without cancers
as a control group after obtaining their consent.
Isolation and Detection of Circulating Tumor Cells
Using the CellSearch System
The 10-mL blood specimens were drawn into the
CellSave Preservative Tubes (Janssen Diagnostics, LLC).
Specimens were maintained at room temperature and pro-
cessed within 72 h after collection. All assessments were
performed by technical assistants who were blinded to the
patients’ clinicopathological data. The CellSearch system
was used for the isolation and enumeration of CTCs, and
7.5 mL of the 10 mL in the tubes were assessed by this
assay. It consists of a semiautomated system for prepara-
tion of a sample and is used with the CellSearch Epithelial
Cell Kit. The procedure enriches the sample for cells ex-
pressing EpCAM with antibody-coated magnetic beads,
and it labels the nucleus with the fluorescent nucleic acid
dye 4, 6-diamidino-2-phenylidole dihydrochloride (DAPI).
Fluorescently labeled monoclonal antibodies specific for
leukocytes (CD45-allophycocyan) and epithelial cells
(cytokeratin 8, 19, 19-phycoerythin) are used to distinguish
epithelial cells from leukocytes. The identification and
enumeration of CTCs were performed with the use of the
Celltracks analyzer II, a semiautomated, fluorescence-
based, microscopy system that permits computer-generated
reconstruction of cellular images. CTCs were defined as
nucleated cells lacking CD45 and expressing cytokeratin
(Supplement Fig. 1A). The criteria used in the CellSearch
system to define a tumor cell have been described previ-
ously.13,14 Results are expressed as the number of CTCs
per 7.5 mL of whole blood.
Cell-Spiking Experiments for Sensitivity and Linearity
of the CellSearch System
A cell-spiking study was done to investigate the sensi-
tivity and linearity of the CellSearch system by spiking a
series of serial dilutions of TE8, TE9, KYSE50, KYSE220
and KYSE270 (1000, 100, 50, 10, 5, and 0 cells) into whole
blood obtained from a normal healthy volunteer without
cancer. This in vitro experiment was repeated three times
to validate its reproducibility.
Clinical Follow-up
All patients were followed-up by physical examinations
and routine blood tests including serum tumor marker tests
(CEA and SCC) every month and computed tomography
(CT) examination every 3 months. Follow-up data were
obtained with a median follow-up period of 10.3 (range
0.3–36.4) months.
Statistical Analysis
Chi square and Fisher’s exact tests were used to com-
pare CTC status with categorical clinicopathological
factors. The Kaplan–Meier method was used for survival
analysis, and the differences in survival were examined by
the log-rank test. Prognostic factors were assessed by
univariate and multivariate analyses (Cox proportional
hazard regression model). All statistical calculations were
performed using SAS statistical software (SAS Institute.
Inc., Cary, NC). p\ 0.05 was considered significant.
RESULTS
Sensitivity of the CellSearch System in the Cell-Spiking
Study
Regression analysis of the number of observed tumor
cells versus the number of expected tumor cells produced a
correlation coefficient of 0.980 (Supplement Fig. 1B).
CTC Analysis in Healthy Volunteers
No CTCs were identified in all blood specimens of the 15
healthy volunteers. In this study, a positive result was defined
as the presence of one or more CTCs per 7.5 mL of blood.
Analysis of CTCs in Clinical Blood Samples of Patients
with ESCC
CTCs were identified in 25 of 90 patients (27.8 %)
before treatment. The CellSearch system demonstrated 12
patients with one CTC, 4 patients with two CTCs, 5 patients
with 3–9 CTCs, 2 patients with 10–99 CTCs, and 2 patients
with C100 CTCs (Supplement Fig. 2). CTCs were identi-
fied in 7 patients (19.4 %) in the neoadjuvant therapy group
and in 18 patients (33.3 %) in the unresectable group.
Relationship Between CTC Status and
Clinicopathological Findings
CTCs were found in 25 % with cT1-2 tumor, 32.7 % with
cT3 tumor, and 21.2 % with cT4 tumor. Positive rates of
CTC by clinical lymph node status were 0.0 % in cN0,
16.7 % in cN1, 28.6 and 30.6 % in cN3. There was no re-
lationship between CTC status and tumor invasion or lymph
node metastasis. CTCs were found in 17.7 % without distant
metastases and 50.0 % with distant metastases. Finally,
CTCs were observed 26.9 % patients in stage II-IIIb, 11.1 %
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in stage IIIc, and 50.0 % in stage IV. The positive rate of
CTCs was significantly related with distant metastasis
(p = 0.002) and with clinical stage status (p = 0.002;
Table 2). Furthermore, the CTC detection rate was 100 % in
pleural dissemination, 50.0 % in hematogenous metastasis,
and 40.0 % in distant lymph node metastasis. There were
significant relationships between CTC status and pleural
dissemination or hematogenous metastases (p\ 0.0001,
p = 0.015; Supplementary Table 1).
Patients receiving chemotherapy had significantly higher
CTC positivity than those receiving CRT (p = 0.004).
Serum CEA, serum SCC, and CRP showed no relationship
with CTCs.
The overall survival rate was significantly lower in pa-
tients with CTCs than in those without CTCs (p = 0.002;
Fig. 1a). The median survival time (MST) of CTC-positive
patients was 261 days and that of CTC-negative patients
was 557 days.
Univariate and Multivariate Analyses of the Detection
of CTCs and Survival
Univariate analyses demonstrated that CTC positivity
(p = 0.003), multiple lymph node metastases (p = 0.002),
distant metastases (p\ 0.0001), serum CRP (p = 0.003),
chemotherapy (p = 0.002), and surgical resection
(p = 0.002) were significantly related to overall survival
(Table 3). Multivariate regression analysis showed that
CTC and serum CRP were independent prognostic factors
(p = 0.021 and p = 0.034).
Evaluation of Therapeutic Efficacy by CTC Status
Before and After Treatment
Blood specimens for second-line analysis were obtained
from 71 patients. The average interval for CTC examina-
tion was 77.9 (range 35–201) days, and that for clinical
diagnosis of treatment efficacy was 98.9 (range 35–210)
days. Partial response (PR), stable disease (SD), and pro-
gressive disease (PD) were seen in 32, 12, and 27 cases,
respectively. CTC positivity after treatment was 21.1 % for
all cases, 40.7 % in the PD group, 16.7 % in the SD group,
and 6.3 % in the PR group. At the CTC analysis after
treatment, patients with CTC showed significantly poor
prognosis rather than patients without CTC (p = 0.005;
Supplement Fig. 3). Six patients had positive CTCs before
and after treatment, 13 patients changed from CTC-positive
to negative, 9 patients changed from CTC-negative to
positive, and 43 patients remained CTC-negative. Six of 9
cases (66.7 %) whose CTC changed from negative to
positive showed PD, and 8 of 13 cases (61.5 %) whose
CTC changed from positive to negative showed PR.
Therefore, CTC status correlated with therapeutic efficacy
(p = 0.034), and CTC positivity after treatment was sig-
nificantly higher in the PD group than in the PR group
(p = 0.004; Table 4). The MST was 128 days in patients
who remained CTC-positive, 514 days in patients who
changed from CTC-positive to negative, and more than
557 days in patients without CTCs before treatment. Pa-
tients with CTCs before and after treatment showed
significantly poorer prognosis than patients whose CTC
changed positive to negative (p = 0.002) and patients
without CTCs before treatment (p\ 0.0001). In contrast,
patients whose CTC changed positive to negative had a







Male 22 56 0.816
Female 3 9
Age
\65 14 33 0.656
C65 11 32
cT factor
1–3 18 39 0.284
4 7 26
cN factor
0–2 10 30 0.598
3 15 35
cM factor
0 11 51 0.002
1 14 14
c Stage




Negative 18 57 0.085
Positive 7 8
Serum SCC
Negative 11 22 0.374
Positive 14 43
CRP
\0.4 9 30 0.381
C0.4 16 35
Treatment
Chemotherapy 13 13 0.004
CRT 12 52
Surgical resection
No 22 52 0.359
Yes 3 13
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good prognosis, as well as patients without CTCs before
treatment (p = 0.323; Fig. 1b).
DISCUSSION
Various methods for detection of CTCs have been
attempted by molecular biological approaches, such as
RT-PCR assays in gastrointestinal tract cancer.5–11 Several
investigators have reported that the detection of CTCs us-
ing RT-PCR is useful to predict the prognosis in patients
with ESCC.6,12 However, the clinical significance of CTCs
remains unclear, because molecular techniques by mRNA
amplification may detect not only live tumor cells but also
dead tumor cells.
In this study, a morphological technique was used for
CTC detection, and this method can identify viable cancer
cells within peripheral blood. The CellSearch System
(CSS) began in 1999 and led to the first standardized, FDA-
cleared, semiautomatic system that can capture and quan-
tify circulating tumor cells in peripheral blood. To date,
many studies using CSS have been published in patients
with breast, prostate, colorectal, and other solid cancers,
and these reports indicated the clinical usefulness of CSS
monitoring as a ‘‘liquid biopsy’’ for patients with
metastatic cancers.13–15,21 However, clinical studies of a
large number of ESCC patients have not been reported. In
the present study, we evaluated the relationship between
CTC and clinicopathological factors or prognosis. The
presence of CTCs was significantly correlated with distant
metastases, such as pleural dissemination and hematoge-
nous metastases (p = 0.002), although positive expression
of CTCs in distant metastases was lower than expected. For
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FIG. 1 a Twenty-five of 90 patients had positive CTCs. The overall
survival rate was significantly lower in patients with CTCs than in
those without CTCs (p = 0.002). The median survival times were
261 days in patients with CTCs and 557 days in patients without
CTCs. b In 71 cases, blood samples were collected before and after
treatment. Patients with CTCs before and after treatment showed a
poorer prognosis than patients without CTCs before and after
treatment (p\ 0.0001). Patients who became CTC-negative after
treatment had a good prognosis, similar to that of patients without
CTCs before treatment (p = 0.002)
TABLE 3 Univariate and multivariate analyses (n = 90)
Independent factors Univariate analysis Multivariate analysis
Hazard ratio (95 % CI) p value Hazard ratio (95 % CI) p value
Age (\65 vs. C5) 0.89 (0.44–1.76) 0.728
Gender (female vs. male) 1.87 (0.79–3.97) 0.146
CTC before treatment (p vs. n) 2.91 (1.44–5.80) 0.003 2.56 (1.15–5.68) 0.021
cT factor (cT4 vs. cT1-3) 1.70 (0.83–3.38) 0.144
cN factor (cN3 vs. cN0-2) 3.31 (1.55–7.88) 0.002 2.26 (0.89–6.24) 0.089
cM factor (cM1 vs. cM0) 5.68 (2.72–12.06) \0.0001 2.18 (0.82–5.81) 0.117
CEA (positive vs. negative) 1.18 (0.44–2.68) 0.714
SCC (positive vs. negative) 1.35 (0.67–2.86) 0.412
CRP (C0.4 vs.\0.4) 3.01 (1.44–6.87) 0.003 2.33 (1.06–5.56) 0.034
Treatment (chemotherapy vs. CRT) 3.30 (1.60–6.71) 0.002 1.38 (0.54–3.43) 0.499
Surgical resection (yes/no) 0.210 (0.05–0.60) 0.002 0.45 (0.10–1.52) 0.211
CI confidence interval
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CTC-positive rates, sensitivity is higher with RT-PCR than
with CSS. However, there might be false-positives, be-
cause the PT-PCR method is not able to demonstrate
cancer cells visually. On the other hand, the false-positive
rate with the CSS is thought to be extremely low, because it
is possible to morphologically confirm the presence of
cells. Some cases, however, might be missed (false-nega-
tives), because the EpCAM as an epithelial marker is not
always expressed in all CTCs, and these EpCAM-negative
CTCs may be undetectable by the CSS. One of the reasons
for this is the presence of an epithelial-mesenchymal
transition (EMT) in CTCs. The EMT is one of the impor-
tant pathways for tumor cells to dissociate and migrate into
the peripheral blood stream.22 Yu reported that CTCs si-
multaneously expressed mesenchymal and epithelial
markers, but mesenchymal cells were highly enriched in
CTCs.23 EpCAM-positive CTCs may be the tip of the
iceberg of total CTCs. Although CSS is able to detect only
epithelial cancer cells, EpCAM-CTC was associated with a
worse prognosis in patients with ESCC than in CTC-
negative cases (MST: 261 vs. 557 days, p = 0.002) in the
present study. This result obviously indicated the clinical
significance of EpCAM-CTC as a prognostic indicator.
Some reports discussed the relationships between the
CTC transition and prognosis.24–26 Smerage et al. demon-
strated that metastatic breast cancer patients with
persistently increased CTCs after one cycle of first-line
chemotherapy showed a poorer prognosis than patients
without CTCs.24 In the present study, CTC expression at the
second-line assessment and therapeutic efficacy were
highly related (Table 4; p = 0.034). Patients with CTC
after treatment showed a significantly poor prognosis than
patients without CTC (p = 0.005; Supplement Fig. 3). In
addition, the prognosis of patients whose CTC changed
positive to negative was improved as well as that of patients
without CTCs before treatment (Fig. 1b). Furthermore,
patients with CTC after treatment showed a shorter pro-
gression-free survival time rather than patients without
CTC (mean time; 73 vs. 326 days, p\ 0.001). Treatment
efficacy was assessed about 3 weeks after second-line
samples were collected. Therefore, the CTC examination as
a ‘‘liquid biopsy’’ may be able to predict therapeutic effi-
cacy earlier than conventional imaging examinations.
CONCLUSIONS
The evaluation of CTCs in peripheral blood is a useful
tool for predicting tumor progression and prognosis in
patients with ESCC. Furthermore, the monitoring of CTC
status may serve as a promising approach for calculating on
the therapeutic efficacy.
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